Results 271 to 280 of about 113,897 (352)

Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions

Cancer, Volume 132, Issue S1, 1 June 2026.
Abstract Antibody–drug conjugates (ADCs) represent a major advance in precision oncology, combining the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By enabling targeted intracellular delivery of highly potent payloads, ADCs aim to maximize antitumor activity while minimizing systemic toxicity. This review summarizes
André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo   +3 more
wiley   +1 more source

Comprehensive treatment for two patients with small cell neuroendocrine carcinoma of the liver: A case report and literature review. [PDF]

Oncol Lett
Feng R, Wang H, Zhao Y, Zhang X, Tuo H, Xu X.   +5 more
europepmc   +1 more source

Patients With Stage III PLCNEC Advocated for Radiotherapy Combined With Chemotherapy While With Stage IV Focus on Individualized Management: Evidence From SEER

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background PLCNEC is a rare and highly aggressive lung cancer with a poor prognosis. Multimodal therapy, primarily chemotherapy‐based, is the standard for advanced PLCNEC, but the role of radiotherapy remains unclear. Methods We analyzed 1086 PLCNEC patients receiving chemotherapy from the Surveillance, Epidemiology, and End Results (SEER ...
Yuze Zhao, Guantong Liu, Haitao Li, Yu Li, Ting Lin, Zefeng Xie   +5 more
wiley   +1 more source

Analysis of prognostic factors for advanced pancreatic neuroendocrine carcinoma: A population-based study. [PDF]

Medicine (Baltimore)
Zhang J, Zhang S, Xu Y, Wang X, Cheng J, Leng X.   +5 more
europepmc   +1 more source

MITF Gain‐of‐Function Mutation in Metastatic Prostate Cancer: A Rare Finding With Potential Therapeutic Significance

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Prostate cancer is the most common non‐cutaneous malignancy in men and remains a leading cause of cancer‐related mortality, particularly in aggressive variants. These tumors are usually associated with alterations in TP53, RB1, and PTEN.
Paul J. Pecorin, Nyembezi Dhliwayo, Matthew Demetrious, Ludimila Cavalcante, Veronica Rodriguez‐Bravo, Josep Domingo Domenech, Thomas Westbrook   +6 more
wiley   +1 more source

Metachronous Primary Pancreatic Neuroendocrine Tumor and Adenocarcinoma: A Case Report

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with most patients presenting with advanced disease. Surgical resection remains the only potentially curative option, yet recurrence rates are high. Case We present a rare case of metachronous primary pancreatic neuroendocrine tumor (PanNET) and PDAC in a 71‐year‐old ...
Anastasia S. Fatyanova, Maria E. Kalinina, Dina F. Islamova, Igor O. Shchekoturov, Julia V. Lerner, Nadezhda A. Stashevskaya, Pavel Burko, Ilias Miltiadis   +7 more
wiley   +1 more source

Integrated Molecular and Functional Characterization of Cervical Small-Cell Neuroendocrine Carcinoma Using a 3D Organoid Model. [PDF]

Int J Mol Sci
Sohel HI, Zahan UF, Ishikawa M, Kanno K, Yamashita H, Nakayama K, Kyo S.   +6 more
europepmc   +1 more source

Sensing and Communicating β‐Cell Stress in the Context of T1D Etiology: New Opportunities for Therapeutic Impact

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
Type 1 diabetes (T1D) results from the immune‐mediated destruction of insulin‐producing pancreatic β‐cells. Recent human studies show that early β‐cell stress maladaptations precede overt immune cell infiltration. DOC2B, a vesicle secretion regulatory protein that supports β‐cell functionality and resilience against stress, declines early in T1D ...
Diana Esparza, Chathurani S. Jayasena, Tijana Jovanovic‐Talisman, Debbie C. Thurmond   +3 more
wiley   +1 more source

Leptomeningeal metastasis from large-cell neuroendocrine carcinoma of the cervix: a case report and literature review. [PDF]

Front Oncol
Xu P, Wang ZJ, Dang XM, Zhu BY, Zheng ZC.   +4 more
europepmc   +1 more source

Epigenetic evolution of bladder cancer from cellular origin to clinical translation

Clinical and Translational Discovery, Volume 6, Issue 3, June 2026.
EpiTrace‐based lineage inference supports a proposed model in which TM4SF1‐positive plastic cancer subpopulations contribute to intratumoural heterogeneity and therapy resistance in bladder cancer. This framework links epigenetic tumour evolution to urine tumour DNA methylation‐based detection and conditionally reprogrammed cell‐based ex vivo drug ...
Kaiyu Qian, Zilin Xu, Zhizhuang Chen, Mengxue Yu, Hongwei Peng, Fangjin Chen, Gang Wang, Yu Xiao, Lingao Ju   +8 more
wiley   +1 more source